Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong Sells 10,845 Shares

Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong sold 10,845 shares of the stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $3.83, for a total value of $41,536.35. Following the completion of the sale, the chief financial officer now directly owns 471,727 shares of the company’s stock, valued at approximately $1,806,714.41. The trade was a 2.25 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Stephen Furlong also recently made the following trade(s):

• On Monday, February 10th, Stephen Furlong sold 14,836 shares of Neuronetics stock. The shares were sold at an average price of $3.28, for a total value of $48,662.08.

Neuronetics Trading Up 11.8 %

NASDAQ STIM opened at $4.36 on Monday. The company has a market cap of $132.33 million, a PE ratio of -3.54 and a beta of 2.17. The company has a current ratio of 3.16, a quick ratio of 2.87 and a debt-to-equity ratio of 4.90. Neuronetics, Inc. has a 12 month low of $0.52 and a 12 month high of $5.07. The stock has a 50 day moving average of $2.20 and a 200-day moving average of $1.41.

Institutional Investors Weigh In On Neuronetics

Large investors have recently made changes to their positions in the stock. Tradewinds LLC. bought a new stake in Neuronetics in the 4th quarter valued at $32,000. XTX Topco Ltd bought a new stake in Neuronetics in the 4th quarter valued at $49,000. Landscape Capital Management L.L.C. bought a new stake in Neuronetics in the 3rd quarter valued at $53,000. GSA Capital Partners LLP raised its stake in Neuronetics by 64.5% in the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock valued at $60,000 after acquiring an additional 30,837 shares during the period. Finally, David J Yvars Group raised its stake in Neuronetics by 47.1% in the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after acquiring an additional 14,825 shares during the period. Institutional investors and hedge funds own 53.59% of the company’s stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.